{"id":"https://openalex.org/W628606000","doi":"https://doi.org/10.1007/s00280-015-2748-1","title":"Pharmacokinetic drug\u2013drug interaction assessment of peptibody trebananib in combination with chemotherapies","display_name":"Pharmacokinetic drug\u2013drug interaction assessment of peptibody trebananib in combination with chemotherapies","publication_year":2015,"publication_date":"2015-06-02","ids":{"openalex":"https://openalex.org/W628606000","doi":"https://doi.org/10.1007/s00280-015-2748-1","mag":"628606000","pmid":"https://pubmed.ncbi.nlm.nih.gov/26032239"},"language":"en","primary_location":{"id":"doi:10.1007/s00280-015-2748-1","doi":"https://doi.org/10.1007/s00280-015-2748-1","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00280-015-2748-1","pdf_url":null,"source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033819205","display_name":"Benjamin M. Wu","orcid":"https://orcid.org/0000-0001-6443-3671","observed_orcids":["https://orcid.org/0000-0001-6443-3671"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Benjamin Wu","raw_affiliation_strings":["Clinical Pharmacology, Modeling and Simulations Group, Department of Medical Sciences, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91310, USA, wub@amgen.com","Clinical Pharmacology, Modeling and Simulations Group, Department of Medical Sciences, Amgen Inc., Thousand Oaks, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology, Modeling and Simulations Group, Department of Medical Sciences, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91310, USA, wub@amgen.com","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Clinical Pharmacology, Modeling and Simulations Group, Department of Medical Sciences, Amgen Inc., Thousand Oaks, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029985940","display_name":"Rebeca Melara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rebeca Melara","raw_affiliation_strings":["Clinical Pharmacology, Modeling and Simulations Group, Department of Medical Sciences, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91310, USA","Clinical Pharmacology, Modeling and Simulations Group, Department of Medical Sciences, Amgen Inc., Thousand Oaks, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology, Modeling and Simulations Group, Department of Medical Sciences, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91310, USA","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Clinical Pharmacology, Modeling and Simulations Group, Department of Medical Sciences, Amgen Inc., Thousand Oaks, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001183616","display_name":"Erik Rasmussen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erik Rasmussen","raw_affiliation_strings":["Department of Biostatistical Sciences, Amgen Inc., Thousand Oaks, CA, USA","Department of Biostatistical Sciences, Amgen Inc., Thousand Oaks, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistical Sciences, Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Department of Biostatistical Sciences, Amgen Inc., Thousand Oaks, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101781171","display_name":"Lei Zhou","orcid":"https://orcid.org/0000-0003-4652-4179","observed_orcids":["https://orcid.org/0000-0003-4652-4179"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lei Zhou","raw_affiliation_strings":["Department of Biostatistical Sciences, Amgen Inc., Thousand Oaks, CA, USA","Department of Biostatistical Sciences, Amgen Inc., Thousand Oaks, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistical Sciences, Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Department of Biostatistical Sciences, Amgen Inc., Thousand Oaks, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044823077","display_name":"Teresa Wong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Teresa Wong","raw_affiliation_strings":["Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, CA, USA","Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., Thousand Oaks, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., Thousand Oaks, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011416414","display_name":"Cindy Kitahara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cindy Kitahara","raw_affiliation_strings":["Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, CA, USA","Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., Thousand Oaks, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., Thousand Oaks, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107391673","display_name":"Mark Ma","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Ma","raw_affiliation_strings":["Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, CA, USA","Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., Thousand Oaks, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Department of Pharmacokinetics and Drug Metabolism, Amgen, Inc., Thousand Oaks, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jessica Lu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessica Lu","raw_affiliation_strings":["Clinical Pharmacology, Modeling and Simulations Group, Department of Medical Sciences, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91310, USA","Clinical Pharmacology, Modeling and Simulations Group, Department of Medical Sciences, Amgen Inc., Thousand Oaks, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology, Modeling and Simulations Group, Department of Medical Sciences, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91310, USA","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Clinical Pharmacology, Modeling and Simulations Group, Department of Medical Sciences, Amgen Inc., Thousand Oaks, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056083434","display_name":"Erick C. Gamelin","orcid":"https://orcid.org/0009-0007-8408-2523","observed_orcids":["https://orcid.org/0009-0007-8408-2523"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erick Gamelin","raw_affiliation_strings":["Department of Medical Sciences, Amgen Inc., Thousand Oaks, CA, USA","Department of Medical Sciences, Amgen Inc, Thousand Oaks, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Sciences, Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Department of Medical Sciences, Amgen Inc, Thousand Oaks, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103863170","display_name":"Cheryl A. Pickett","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cheryl A. Pickett","raw_affiliation_strings":["Clinical Development Oncology, Amgen Inc., Thousand Oaks, CA, USA","Clinical Development Oncology, Amgen Inc., Thousand Oaks, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development Oncology, Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Clinical Development Oncology, Amgen Inc., Thousand Oaks, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112872664","display_name":"Yu\u2010Nien Sun","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yu-Nien Sun","raw_affiliation_strings":["Clinical Pharmacology, Modeling and Simulations Group, Department of Medical Sciences, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91310, USA","Clinical Pharmacology, Modeling and Simulations Group, Department of Medical Sciences, Amgen Inc., Thousand Oaks, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology, Modeling and Simulations Group, Department of Medical Sciences, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91310, USA","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Clinical Pharmacology, Modeling and Simulations Group, Department of Medical Sciences, Amgen Inc., Thousand Oaks, USA","institution_ids":["https://openalex.org/I1320553840"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5033819205"],"corresponding_institution_ids":["https://openalex.org/I1320553840"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":null,"fwci":0.3881,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.66197802,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"76","issue":"2","first_page":"243","last_page":"250"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.47780001163482666,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.47780001163482666,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.09470000118017197,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.05739999935030937,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trebananib","display_name":"trebananib","score":1.0},{"id":"https://openalex.org/keywords/peptibody","display_name":"peptibody","score":0.8529999852180481},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.8560000061988831},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9580000042915344},{"id":"https://openalex.org/keywords/chemotherapy","display_name":"chemotherapy","score":0.640999972820282},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.996999979019165},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.7919999957084656},{"id":"https://openalex.org/keywords/pegylated-liposomal-doxorubicin","display_name":"pegylated liposomal doxorubicin","score":0.9850000143051147},{"id":"https://openalex.org/keywords/topotecan","display_name":"topotecan","score":0.9869999885559082},{"id":"https://openalex.org/keywords/capecitabine","display_name":"capecitabine","score":0.9779999852180481},{"id":"https://openalex.org/keywords/lapatinib","display_name":"lapatinib","score":0.9959999918937683},{"id":"https://openalex.org/keywords/5-fluorouracil","display_name":"5-fluorouracil","score":0.9580000042915344},{"id":"https://openalex.org/keywords/irinotecan","display_name":"irinotecan","score":1.0},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.996999979019165},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":0.9229999780654907},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9490000009536743},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.9729999899864197},{"id":"https://openalex.org/keywords/dose-adjustment","display_name":"dose adjustment","score":0.875}],"concepts":[{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.832508385181427},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7184051275253296},{"id":"https://openalex.org/C2910466267","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug-drug interaction","level":3,"score":0.702319324016571},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6481910347938538},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5281051397323608},{"id":"https://openalex.org/C97320921","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug interaction","level":3,"score":0.49764326214790344}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/s00280-015-2748-1","doi":"https://doi.org/10.1007/s00280-015-2748-1","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00280-015-2748-1","pdf_url":null,"source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},{"id":"pmid:26032239","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26032239","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer chemotherapy and pharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W1582389385","https://openalex.org/W1616753723","https://openalex.org/W1722653117","https://openalex.org/W1836451026","https://openalex.org/W1982110083","https://openalex.org/W1985604577","https://openalex.org/W1996752872","https://openalex.org/W1996859043","https://openalex.org/W2002422795","https://openalex.org/W2045485835","https://openalex.org/W2090935442","https://openalex.org/W2091582819","https://openalex.org/W2094075734","https://openalex.org/W2102195694","https://openalex.org/W2119465075","https://openalex.org/W2120022879","https://openalex.org/W2122927195","https://openalex.org/W2131970746","https://openalex.org/W2162888433","https://openalex.org/W2166811349","https://openalex.org/W2443039709","https://openalex.org/W2807394859"],"related_works":["https://openalex.org/W2153342244","https://openalex.org/W2602042865","https://openalex.org/W2472000057","https://openalex.org/W2164548254","https://openalex.org/W2156969792","https://openalex.org/W2171634902","https://openalex.org/W4409631446","https://openalex.org/W1898871412","https://openalex.org/W2969551833","https://openalex.org/W2020989264"],"abstract_inverted_index":null,"counts_by_year":[{"year":2016,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}